Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases

Background/Aim: Radium -223 therapy has been reported to improve prognosis in patients with castrationresistant prostate cancer (CRPC) and bone metastases. Occasionally, radium -223 and androgen receptor signaling inhibitors (ARSIs) are used in combination for disease control, but the efficacy of this combination is unclear. This study assessed the efficacy of the addition of enzalutamide in patients treated with radium -223. Patients and Methods: We included patients with CRPC and bone metastases who were treated with radium -223 at our institution. Patients were assigned to the enzalutamide combination group or non -combination group. We compared progression -free survival (PFS), overall survival (OS), and the completion rate of radium -223 between the two groups. Results: In total, 39 patients with CRPC were included in this retrospective study. The median follow-up duration was 8.8 months. The enzalutamide combination and non -combination groups included 22 (56.4%) and 17 patients (43.6%), respectively. Median PFS was 11.3 months [95% confidence interval (CI)=3.9-19.9] in the combination group, versus 3.0 months (95%CI=1.9-5.5) in the non -combination group (p=0.004). Median OS did not significantly differ between the groups. The radium -223 completion rate was higher in the combination group than in the non -combination group (72.7% vs. 35.3%, p=0.026). Conclusion: The combined use of enzalutamide with radium -223 therapy improved PFS and treatment completion rates in patients with CRPC and bone metastases. This combination may be associated with a more favorable prognosis.